Immunological parameters as biomarkers of response to MicroCrystalline Tyrosine-adjuvanted mite immunotherapy
Justicia, José L. (Allergy Therapeutics Ibérica (Barcelona))
Padró, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Roger, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Moreno, Francisco (Dr. Lobatón Clinic (Càdis))
Rial, Manuel J. (Complejo Hospitalario Universitario de A Coruña)
Parra, Antonio (Complejo Hospitalario Universitario de A Coruña)
Valero, Antonio (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Malet, Alfonso (Al·lergo Centre (Barcelona, Catalunya))
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Boronat, Anna (Allergy Therapeutics Ibérica (Barcelona))
Torán-Barona, Carla (Allergy Therapeutics Ibérica (Barcelona))

Fecha:	2021
Resumen:	Despite the effectiveness of allergen immunotherapy (AIT), some patients are unresponsive for reasons still unknown; yet validated response biomarkers remain unavailable. To analyze immunological parameters as biomarkers to monitor and predict clinical response to a MicroCrystalline Tyrosine-adjuvanted house dust mite (HDM) AIT in patients with allergic rhinitis (AR). Observational, prospective, multicenter study including adult patients (aged 18-65 years) with AR, with and without asthma, sensitized to the HDM Dermatophagoides pteronyssinus (DP) and prescribed Acarovac Plus® DP 100% in the routine practice. Serum concentrations of total IgE, specific IgE, specific IgG4, IL-4, IL-5, IL-10, IL-13, and IFN-γ were compared between baseline and 12 months after AIT. The relationship between patients' baseline immunological profiles and classification as low, high, and non-responders and between their sensitization profile to DP allergens and effectiveness were analyzed. Of 141 patients recruited, 118 (mean [SD] age of 33. 6 [9. 5] years) were evaluable. One year after treatment, Der p 1-specific IgE, DP-specific IgG4, and IL-10 increased by a mean (SD) of 3. 4 (13. 6) kU/L (p = 0. 016), 0. 43 (0. 55) mg/L (p < 0. 0001), and 1. 35 (7. 56) pg/mL (p = 0. 033), respectively. Non-responders showed increased baseline levels of IL-13 compared to high responders (p = 0. 037). Changes in effectiveness variables between baseline and after AIT were similar regardless of the sensitization profile. Non-responsive patients to AIT showed increased baseline IL-13 concentrations, suggesting its value as prognostic biomarker. DP-specific AIT increased Der p 1-specific IgE, DP-specific IgG4, and IL-10 concentrations in patients with AR. All patients benefited from treatment regardless of their sensitization profile to major DP allergens.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	House dust mite ; Allergic rhinitis ; Subcutaneous allergen immunotherapy ; Microcrystalline Tyrosine ; Immunological biomarkers ; Sensitization profile ; Allergoid ; Adjuvant
Publicado en:	The World Allergy Organization Journal, Vol. 14 (june 2021) , ISSN 1939-4551

DOI: 10.1016/j.waojou.2021.100545
PMID: 34178239

12 p, 656.3 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados